Quick Answer
MoonLake Immunotherapeutics reported Stockholders Equity of $304.48 million for fiscal year 2025.
MoonLake Immunotherapeutics Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $304.48M | -31.9% |
| 2024 | $446.82M | -9.9% |
| 2023 | $495.68M | +913.7% |
| 2022 | $48.90M | +519.9% |
| 2021 | -$11.65M | -11033.6% |
| 2021 | $106.5K | +104.2% |
| 2020 | -$2.52M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $288.91M | -40.8% | -18.3% |
| June 30, 2025 | $353.73M | -32.1% | -13.2% |
| March 31, 2025 | $407.52M | -24.9% | -8.8% |
| December 31, 2024 | $446.82M | -9.9% | -8.5% |
| September 30, 2024 | $488.20M | +14.9% | -6.2% |
| June 30, 2024 | $520.66M | +6.3% | -4.0% |
| March 31, 2024 | $542.55M | +1191.8% | +9.5% |
| December 31, 2023 | $495.68M | +913.7% | +16.6% |
- MoonLake Immunotherapeutics showed a decrease of -31.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, MoonLake Immunotherapeutics’s stockholders equity has grown by 12200.4% (from -$2.52 million to $304.48 million).
- The most recent figure is from MoonLake Immunotherapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: